TECH Joins Forces With Oxford Nanopore Technologies: Stock to Gain?

Bio-Techne Corporation TECH recently announced Asuragen’s — a Bio-Techne brand —partnership with Oxford Nanopore Technologies to launch the AmplideX Nanopore Carrier Plus Kit. The research-use-only AmplideX Nanopore Carrier Plus Kit is a new genetic panel that will support software analysis for carrier screening research.  The latest partnership is expected to bolster the company’s Diagnostics and Spatial Biology segment.TECH Stock Likely to Gain From the DevelopmentSince the announcement, Bio-Techne’s shares have dipped 0.9%, closing at $61.19 in yesterday’s session.  Asuragen brand is well known for its designed, high-quality molecular diagnostic products. The Asuragen kit business continues to gain strong momentum. Asuragen’s recent partnership with Oxford Nanopore Technologies accurately delivers an ideal solution for labs looking to provide superior and cost-effective carrier screening research results. Accordingly, we expect the latest partnership to boost the market sentiment toward TECH stock in the upcoming days.Bio-Techne has a market capitalization of $9.76 billion. The Zacks Consensus Estimate for fiscal 2025 earnings indicates a 6.8% year-over-year increase on a 5.5% revenue improvement. In the trailing four quarters, it delivered an average earnings surprise of 5.37%. Importance of AmplideX Nanopore Carrier Plus KitIn 2021, the American College of Medical Genetics and Genomics (“ACMG”) updated its recommendations for carrier screening to include the genes that cannot be analyzed by standard short-read sequencing. Until now, laboratories have relied on multiple test technologies, including MLPA, Sanger sequencing, qPCR, long-range PCR and others, to analyze the recommended genes.The AmplideX Nanopore Carrier Plus Kit provides a single streamlined method and delivers comprehensive sequencing data compared to alternative assays. By combining novel AmplideX long-range PCR with nanopore long reads, it directly captures large genomic variants. The 11-gene panel includes the most prevalent recommended genes that cannot be detected accurately with legacy short-read sequencing methods. Henceforth, it will help labs replace a patchwork testing approach with a single workflow to simplify sample-to-answer results. The kit also includes software to enable straightforward analysis without the need for advanced bioinformatics resources. The kit targets genes like CFTR, CYP21A2, F8 inversions, FMR1, GBA, HBA1, HBA2, HBB, SMN1, SMN2 and TNXB.Industry Prospects Favor Bio-TechPer a report by TechSci Research, the global Nanopore Sequencing market was valued at $330.59 million in 2023 and is expected to witness a compound annual growth rate (CAGR) of 18.07% through 2029. The key factors driving the market growth include the increasing demand for DNA sequencing stems and technological advancements, which provide distinct benefits compared to traditional techniques. Image Source: Zacks Investment ResearchAnother Development by TECH’s Asuragen BrandIn December 2024, Asuragen launched a highly sensitive ESR1 mutation monitoring assay. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) metastatic breast cancer. The new ESR1 mutation assay, featuring the QuantideX qPCR ESR1 exoMutation Kit paired with the ExoLution Plus cfDNA + exoRNA Isolation Kit, is designed to detect 11 ESR1 ligand-binding domain mutations in samples at very high sensitivity.TECH Stock Price PerformanceIn the past year, TECH’s shares have declined 18.3% compared with the industry’s decline of 8.1%.TECH’s Zacks Rank and Key PicksBio-Techne currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the broader medical space are Masimo MASI, Boston Scientific BSX and Cardinal Health CAH. At present, Masimo carries a Zacks Rank #1 (Strong Buy), whereas Boston Scientific and Cardinal Health carry a Zacks Rank #2 (Buy) each. Masimo’s shares have rallied 50.4% in the past year. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Estimates for MASI’s 2025 earnings per share (EPS) have increased 10% to $5.07 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 14.41%. In the last reported quarter, it posted an earnings surprise of 20.8%.Estimates for Boston Scientific’s 2025 EPS have jumped 2.9% to $2.85 in the past 30 days. Shares of the company have surged 55.5% in the past year compared with the industry’s growth of 6.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.25%. In the last reported quarter, it delivered an earnings surprise of 7.7%.Estimates for Cardinal Health’s fiscal 2025 EPS have increased 1.8% to $7.94 in the past 30 days. Shares of the company have jumped 14.7% in the past year against the industry’s 6.5% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.64%. In the last reported quarter, it delivered an earnings surprise of 10.3%.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Bio-Techne Corp (TECH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks